Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience. Affecting more than 21 million people globally, DME ...

At the 2025 Annual Meeting, I had the privilege of 1 I have been working on over the past year—exploring how retinal imaging might help detect early signs of Alzheimer disease (AD), especially in ...

Biotechnology company Nanoscope Therapeutics recently announced the formation of Vision Advisory Committee (VAC). 1 VAC is “a group of renowned experts in retina treatment and commercialization,” a ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Christine Kay, MD, presented interim 1-year data from a phase 1/2 study of an investigational gene therapy (OPGx-LCA5; Opus Genetics) for LCA5-related Leber congenital amaurosis at the Clinical Trials ...

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Ahead of the Clinical Trials at the Summit (CTS) meeting in Las Vegas, Nevada, Victor Gonzalez, MD, shared an overview of his presentation. Dr. Gonzalez is a trial investigator in the REMAIN follow-up ...

Treatment provided suboptimal control of the nAMD in the right eye, with a visual acuity (VA) of 20/40 and central subfield thickness (CST) of 397 µm; the left eye VA was 20/30, and the CST was 297 µm ...

The University of Colorado Anschutz Medical Campus’ Department of Ophthalmology has received a $40 million gift. The donor, a patient at the Sue Anschutz-Rodgers Eye Center, has chosen to remain ...

Free diabetic retinopathy (DR) screenings begin this week through a collaboration between Avant Technologies, Ainnova Tech and Grupo Dökka, Fischel Pharmacies and La Bomba Pharmacies, according to a ...

Robert Collier said, “success is the sum of small efforts, repeated day in and day out.” So, as we approach the busiest retina meeting season, remember each small effort and give these pearls a try.